Back

Serina advances SER-252 Parkinson’s study to Cohort 2 after blinded safety review

Verifying
  • Serina Therapeutics advances SER-252’s Phase 1b Parkinson’s study to Cohort 2.
  • Eight patients received the lowest single dose in Cohort 1.
  • Topline single-ascending-dose data are expected in the first half of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.